The benefits of mitral valve reconstruction for operative

Size: px
Start display at page:

Download "The benefits of mitral valve reconstruction for operative"

Transcription

1 Prophylactic Mitral Reconstruction for Mitral Regurgitation Iva A. Smolens, MD, Francis D. Pagani, MD, PhD, G. Michael Deeb, MD, Richard L. Prager, MD, Seema S. Sonnad, PhD, and Steven F. Bolling, MD Section of Cardiac Surgery, Department of Surgery, University of Michigan Hospitals, Ann Arbor, Michigan Background. Mitral regurgitation (MR) will produce myocardial dysfunction. The goal of this study was to review outcomes of mitral valve reconstruction in asymptomatic patients with severe MR. Methods. From 1992 to 2000, 93 asymptomatic patients with degenerative disease and severe MR underwent mitral valve reconstruction. Mean preoperative left ventricular internal diameter diastole was 56 8 mm and ejection fraction was 60% 6%. Mean age was years and mean follow-up months. All patients underwent complex reconstruction. Results. There were no deaths and two late reoperations. One was for systolic anterior motion of the anterior leaflet of the mitral valve requiring valve replacement and one for hemolysis requiring re-repair. There was one perioperative transient ischemic attack and no late thromboembolic events. At follow-up all but 1 patient remains in NYHA class I and all had no MR except in 2 patients at 63 and 89 months. Conclusions. Mitral valve reconstruction for asymptomatic MR can be performed with no mortality and low morbidity before development of left ventricular dysfunction. Early prophylactic repair is advocated in the presence of severe MR if valve reparability is assured. (Ann Thorac Surg 2001;72;1210 6) 2001 by The Society of Thoracic Surgeons The benefits of mitral valve reconstruction for operative correction of mitral regurgitation (MR) are well established. These benefits include low perioperative mortality, preservation of left ventricular (LV) function, avoidance of long-term anticoagulation, decreased thromboembolic complications, a low risk of native valve endocarditis, excellent long-term freedom from reoperation, and improved survival as compared with that of patients undergoing valvular replacement [1 6]. The optimal timing of surgical intervention in MR remains controversial. It is difficult to decide when is the most appropriate time to operate on a patient with chronic MR, as these patients may remain asymptomatic or only mildly symptomatic for a long time. Unfortunately, all the while these patients are experiencing a subtle, relentless, silent deterioration in LV function. Historically surgery was delayed until either the patient was symptomatic or there was evidence of LV dysfunction because all that could be offered to the patient was mitral valve replacement. By the time the patients became symptomatic, however, serious and often irreversible LV dysfunction may have developed [7, 8]. The recognition of the advantages of mitral valve repair over replacement for MR has led to progressively earlier surgical intervention. Most authors and the current American College of Cardiology/American Heart Association guidelines now advocate surgical repair of Presented at the Thirty-seventh Annual Meeting of The Society of Thoracic Surgeons, New Orleans, LA, Jan 29 31, Address reprint requests to Dr Bolling, Section of Cardiac Surgery, The University of Michigan Hospitals, 2120D Taubman Center, Box 0348, Ann Arbor, MI ; sbolling@umich.edu. the mitral valve for MR in patients if more than mild symptoms develop (New York Heart Association [NYHA] functional class II or greater), if the ejection fraction (EF) falls toward 60%, or if the end-systolic dimension approaches 45 mm, even in the absence of symptoms, if the valve appears amenable to repair [7, 9]. Comparable to atrial septal defect repair, which is undertaken in asymptomatic young patients to prevent long-term sequelae of pulmonary hypertension, mitral valve repair should perhaps be considered before distortion of LV function occurs, to prevent long-term sequelae of congestive heart failure [9]. The clinical impact of surgical correction of MR in patients with no symptoms or mild symptoms is still unclear in terms of short- and long-term outcomes. In this study we reviewed a single center s experience of isolated mitral valve repairs in patients with myxomatous disease of the mitral valve with no or only mild symptoms. It is the goal of this study to assess surgical as well as valve-related morbidity and mortality, and to ascertain long-term functional status of the patients. Material and Methods Between July 1992 and December 2000 a total of 1,503 mitral valve operations (repair and replacement) were performed at the University of Michigan. This study was a retrospective review of a single institution s experience with the surgical correction of MR. The inclusion criteria were as follows: (1) mitral valve repair procedure performed between July 1992 and December (2) Preoperative NYHA functional class I or 2001 by The Society of Thoracic Surgeons (01)$20.00 Published by Elsevier Science Inc PII S (01)

2 Ann Thorac Surg SMOLENS ET AL 2001;72: PROPHYLACTIC MITRAL RECONSTRUCTION 1211 Table 1. Mechanism of Mitral Regurgitation Mechanism of Regurgitation Number % Posterior leaflet prolapse Anterior leaflet prolapse 9 10 Bileaflet prolapse Popped chords/flail leaflet II. The patient s functional status was determined by review of their medical records. Patients were classified as NYHA class I if they had no symptoms and as NYHA class II if they had only minimal limitation of physical activity. (3) Isolated moderate-to-severe or severe MR (3 or 4 ) with no associated mitral stenosis as defined by preoperative echocardiography. (4) Degenerative/ myxomatous mitral valve disease as the underlying etiology of the MR. Patients who had a remote history of endocarditis superimposed on the degenerative disease were included. (5) Patients undergoing concomitant closure of a patent foramen ovale or atrial septal defect. The exclusion criteria were as follows: (1) MR attributable solely to geometric distortion of the LV, as seen in patients with dilated or ischemic cardiomyopathy. (2) Mitral regurgitation attributable to anatomic distortion of the mitral valve apparatus, other than that due to degenerative disease of the valve, as seen in rheumatic mitral valve disease or acute endocarditis. (3) Associated or previous surgical procedures including concomitant coronary artery bypass grafting or associated valve procedures. During this study period 1,211 mitral valve repair procedures were performed. Of these, 93 patients corresponded to the inclusion/exclusion criteria and they comprise our study population. The mean age was years (range 21 to 69 years). There were 33 women (35%) and 60 men (65%). In all, 53 patients were in NYHA class I (57%) and 40 (43%) were in NYHA class II. All patients in this study had degenerative/myxomatous disease of the mitral valve as the sole underlying etiology of their MR; the mechanisms of MR are summarized in Table 1. Five of the patients had a remote history of endocarditis (5.3%). Nineteen patients (20.4%) underwent incidental closure of a patent foramen ovale and 3 (3.2%) underwent atrial septal defect (1 patch, 2 primary) closure simultaneous with the mitral valve repair procedure. The severity of MR was assessed by either transthoracic or transesophageal echocardiography. Of the 93 study patients, 89 (96%) had complete preoperative echocardiographic measurements. Eleven (12%) of the 93 study patients had a documented preoperative episode of atrial fibrillation or atrial flutter. The decision to operate on these patients was based on the presence of moderate-to-severe or severe MR (3 or 4 ) and if the valve appeared amenable to repair based on its echocardiographic appearance. Valve repair was attempted and successfully performed in all 93 patients. Mitral valve reconstruction included implantation of an annuloplasty ring in all cases; circumferential (69 cases) and hemi-ring (24 cases). The additional complex repair Table 2. Mitral Valve Repair Techniques Utilized Repair Technique Number % Posterior quadrangular resection Anterior leaflet resection Chordal shortening 4 4 Chordal transposition Gore-Tex prosthetic chords techniques used are outlined in Table 2. All patients underwent intraoperative transesophageal echocardiographic assessment of the valve to ensure that there was no residual MR or mitral stenosis upon completion of the repair procedure. All patients received anticoagulation with warfarin at the time of discharge and were maintained on anticoagulation for 1 month after the procedure, with an International normalized ratio of 2.0 to 2.5. All postoperative patient care was standardized by preestablished pathway protocol. Follow-up data were collected through review of the medical records maintained at our institution. Telephone contact with patients was initiated if follow-up data were not available in the records. Complete follow-up data were available for 87 (94%) patients. Mean follow-up was months, for a cumulative follow-up of 180 patient-years. Statistical Analysis All data are reported as mean one standard deviation. Student s t test for unpaired data was used to analyze the significance of differences between preoperative and postoperative echocardiographic data. The Kaplan-Meier method was used for calculating the complication and risk of reoperation rates. The statistical analysis was performed according to the protocols incorporated in the STATA statistical software package (Stata Corporation, College Station, TX). Statistical significance was defined at a p value less than or equal to Results Mortality There were no deaths, for a 100% 5-year survival rate. Hospital Length of Stay The mean length of stay in the hospital was 4 2 days. Perioperative Morbidity All patients identified with NYHA functional class I or II with 3 to 4 MR and who underwent isolated correction of their MR had repair at the initial operation. No patients were identified as potential mitral valve repair candidates, who then underwent initial mitral valve replacement. One patient required reoperation for bleeding within the first 24 hours after the procedure and there were no adverse sequelae related to this event. Two patients developed significant pericardial effusions in the perioperative period and both were treated with drain-

3 1212 SMOLENS ET AL Ann Thorac Surg PROPHYLACTIC MITRAL RECONSTRUCTION 2001;72: Reoperation-Free Survival and Valve-Related Complications There have been two (2%) late reoperations at 8 and 10 months for valve repair failure. In the first case, the patient underwent anterior leaflet resection, chordal shortenening, and annuloplasty for severe bileaflet prolapse. The cause for reoperation was the late development of significant exercise-induced LV outflow tract obstruction that developed secondary to failure of the chordal shortening procedure. At reoperation, the patient underwent mitral valve repalacement with a mechanical prosthesis. In the second case, the patient underwent postorior leaflet resection and annuloplasty for bileaflet prolapse. The reason for reoperation in this case was the development of severe hemolysis, and at the time of the operation the patient was found to have a ruptured anterior chordal group. This pathology was amenable to rerepair with an anterior leaflet resection and insertion of Gore-Tex (W.L. Gore & Associates, Flagstaff, AZ) prosthetic chords. No deaths occurred with reoperation. At 5 years, the rate of freedom from reoperation was 96.5% 2.5% (CI to ) as shown in Figure 1. One patient (1%) had a thromboembolic event in the immediate postoperative period. This patient had a transient ischemic attack with complete resolution of symptoms. All patients received anticoagulation for the first month after the procedure and there were no anticoagulation-related complications. One patient is maintained on long-term anticoagulation for his prosthetic valve, and to date there have been no significant hemorrhagic complications. Three patients developed mild and selflimiting hemolysis in the postoperative period 3, 8, and 8 months postoperatively. Two of these 3 patients have been noted to have moderate MR (2 ) on follow-up echocardiography, yet they remain asymptomatic. No patients in this study group have had valvular endocarditis following a repair procedure. Five-year freedom from any event (thromboembolism, anticoagulantrelated hemorrhage, hemolysis, infection, mediastinitis, and endocarditis) was 89.6% 5.6% (CI to ) as shown in Figure 2. Fig 1. Actuarial curve of 5-year freedom from reoperation. age procedures without any complications. These 3 patients had significant 30-day perioperative events that required a second intervention, for a cumulative rate of 3.2%. Atrial Fibrillation Eleven (11.8%) patients had a history of atrial arrhythmias at the time of their presentation for surgical evaluation. None of the patients had been in chronic atrial fibrillation. Eighteen (19.5%) patients developed atrial fibrillation in the immediate postoperative period (30 days), all of whom responded to either chemical (15 patients) or electrical (3 patients) cardioversion, and there was no correlation between those patients who had experienced atrial fibrillation preoperatively and postoperatively. All but 1 patient currently (1.1%) remains in sinus rhythm at follow-up. No patients experienced heart block or required permanent pacemaker insertion. Functional Status Preoperatively a total of 53 patients were in NYHA class I (57%) and 40 (43%) were in NYHA class II. Of the 87 patients with complete follow-up data, 86 patients remain in NYHA class I and 1 patient is in NYHA functional class II. Echocardiographic Data As determined by preoperative echocardiographic studies, all patients had grade 3 (37%) or 4 (63%) MR on a scale of 1 to 4, with a mean of The mean preoperative LV end-systolic and end-diastolic diameters were mm and mm, respectively, and only 28 patients (31%) had an LV end-diastolic diameter greater than 60 mm. The mean left atrial diameter was mm. Postoperative two-dimensional echocardiography with Doppler examination was available in 30 (32.3%) patients. The mean follow-up time at which these studies were performed was months after the Fig 2. Actuarial curve of patients free from an event (valve-related episode of thromboemboli, hemorrhage, hemolysis, infection, mediastinitis, endocarditis) in the postoperative period as a function of time after the initial operation.

4 Ann Thorac Surg SMOLENS ET AL 2001;72: PROPHYLACTIC MITRAL RECONSTRUCTION 1213 Table 3. Preoperative and Postoperative Echocardiographic Data valve repair procedure. These echocardiographic data show that the LV chamber dimensions decrease significantly after the repair procedure. The data are summarized in Table 3. The mean grade of residual MR as recorded at late follow-up was , attributable entirely to 3 patients who had grade 2 or greater residual MR at follow-up. Comment Preoperative Follow-up p Value LVIDd LVIDs LAD EF (NS) MR p EF ejection fraction (%); LAD left atrial diameter (mm); LVIDd left ventricular internal diameter diastole (mm); LVIDs left ventricular internal diameter systole (mm); MR mitral regurgitation (grade 1 to 4 ). To consider surgical intervention early in a disease process, it must be demonstrated that the surgical procedure improves the overall survival and quality of life in comparison to the disease process natural course. Degenerative/myxomatous disease of the mitral valve represents the leading cause of isolated MR that requires surgical intervention in the United States [10]. Mitral regurgitation is a progressive disorder that leads to enlargement of the left atrium and ventricle, increased left ventricular filling pressure, and reduced afterload. All of these physiologic alterations contribute to annular dilation and worsening of leaflet coaptation, which then results in more MR [11]. As the MR progresses, dilation and hypertrophy of the LV occur. The clinical markers of LV dysfunction are when the EF falls to less than 60% or the LV diameter at end-systole is greater than 45 mm [7]. Previous studies have demonstrated that the contractile function of the LV is impaired in patients with MR, even in the presence of a normal EF [12]. In patients with severe MR and LV dysfunction, after surgical correction of the regurgitation, there is no demonstrable improvement in contractile function [13]. The presence of LV dysfunction in the postoperative patient carries a poor prognosis, suggesting that operative repair should be considered before the development of the functional impairment. In this study, the decision to operate was based on assessment of the severity of the MR and the feasibility of repair. Myxomatous mitral valve disease in this series was 100% repairable with the initial operative procedure. There were no patients in this series who had an initial preoperative plan of valve repair who ultimately required valve replacement. This success reflects both our routine use of intraoperative transesophageal echocardiography to assess valvular competence postrepair, as well as the surgeons extensive experience with mitral valve reconstruction. In our series, there were no perioperative deaths and only 3 patients had significant 30-day perioperative morbid events for a cumulative operative morbidity risk of 3.2%. Additionally, 18 patients (19.5%) developed perioperative atrial fibrillation, and all of these patients converted back to normal sinus rhythm at 30-day follow-up. Based on our study data as well as that data published in the literature, the short-term perioperative risks of the surgical procedure itself are minimal and deemed to be acceptable. The natural history of medically treated MR is difficult to delineate, with a wide range of survival estimates in the literature [14]. The best data so far are from the study by Ling and colleagues [15], which defined the natural history of MR. In this study the outcomes of 229 patients with isolated MR who were asymptomatic and treated medically were examined. The entire cohort of patients had a significantly reduced survival rate when compared with that of the general population (6.3% mortality/year). Patients who were even transiently in NYHA class III or IV had the highest mortality rate of 34% yearly, and the mortality rate was significant (4.1% yearly) even among those in NYHA functional class I or II with degenerative mitral valve disease. Furthermore, the 10-year survival rate was only 69% for patients in NYHA functional class I with an EF greater than 60%, and 90% of the patients who presented initially in NYHA functional class I or II either underwent surgical correction of the MR (only after they had progressed to NYHA class III or IV) or died. From these data we can conclude that the natural history and survival of patients with MR, even when in NYHA functional class I or II, is worse than the expected mortality rate in the comparable general population [15]. Currently it is accepted practice that patients with symptoms of heart failure (NYHA functional class III or IV) who have a mitral valve amenable to repair should undergo surgical correction for the MR. Although the postoperative outcome for these patients is far better than the medical treatment, a significant number of these patients will incur a notable incidence of LV dysfunction, when allowed to progress to NYHA class III or IV before operative intervention. Operative intervention is now being applied more frequently to patients who are in NYHA functional class I or II with signs of early LV dysfunction (EF 60% or end-systolic diameter 45 mm) [7, 8]. The most controversial group of patients are those with significant MR who are in NYHA functional class I or II with no signs of LV dysfunction. An early operation is a reasonable approach in these patients and represents a new perspective in the treatment of MR. The benefits of early surgical intervention in patients with MR have been reported. Sousa and colleagues [12] reported surgical results on a series of patients who were in NYHA class I or II with grade 3 to 4 isolated MR who underwent mitral valve repair. The overall operative mortality was 1.7%, 5-year freedom from reoperation was 97.0% 0.8%, and 5-year event free survival was 91.0% 2%. Ling and colleagues [15] reported results of operative

5 1214 SMOLENS ET AL Ann Thorac Surg PROPHYLACTIC MITRAL RECONSTRUCTION 2001;72: Fig 3. The number of mitral valve repair procedures performed per year of the study. intervention in a similar patient population in two studies. In a multivariate analysis of patients who underwent surgical correction of MR there was a statistically significantly associated reduction in overall mortality rate. In a later study, these same authors performed a retrospective review comparing two groups of patients. One group of patients were operated on early after the diagnosis of MR was made, whereas the second group of patients being followed medically were operated on when symptoms developed. Despite the early occurrence of symptoms in the first group, the 10-year survival after surgery was superior in the patients operated on earlier than those referred to surgery after development of symptoms. Additionally, the early surgery strategy was followed by a lower incidence of congestive heart failure and chronic atrial fibrillation. This outcome advantage suggested that early surgery is the treatment option to be considered in low-risk candidates with repairable valves and severe MR, regardless of symptoms [16]. We share this philosophy of earlier surgical intervention. In our series we demonstrated, in 93 patients who underwent early mitral valve repair, that this procedure can be performed safely with no mortality and minimal morbidity. In this series, the mean preoperative endsystolic and end-diastolic LV diameters of 39 and 57 mm, respectively, were lower than the guidelines suggested in the literature [7, 9, 13]. This reflects in part our bias toward early surgical intervention in this patient population. The number of repair procedures performed in patients who were asymptomatic or only mildly symptomatic, with degenerative disease, in our institution has also risen dramatically (Fig 3), with only two procedures being performed in 1992 and 41 in In all of the cases in this series, the MR was due to leaflet prolapse secondary to degenerative disease of the valve. Early in the series, 4 patients underwent chordal shortening procedures for anterior leaflet prolapse. Gillinov and associates [17], from the Cleveland Clinic, reported a series of 86 patients analyzing those who underwent reoperation for failure of a mitral valve repair procedure. Rupture of previously shortened chordae was found to be the most common cause of late failure. In this study we had two failures of repair, and in 1 of these patients the failure of the repair was associated with a chordal shortening procedure for the correction of anterior leaflet prolapse. Chordal shortening procedures are no longer performed in our institution, and chordal transposition or use of Gore-Tex prosthetic chords are the favored techniques for the correction of anterior leaflet prolapse. Postoperative EF has been shown to correlate with long-term outcome and to be predicted by preoperative echocardiographic EF as well as by systolic LV diameter [15]. In this series 91% of the patients had late LV systolic dimensions within the normal range. Mitral valve repair in the absence of symptoms achieved the goal of preserving postoperative LV function and should contribute to an excellent long-term late outcome. In this series we achieved a 5-year freedom from reoperation rate of 96.5%. Our freedom from reoperation is similar to, or better than, what is published in other series [1, 2, 5] and demonstrates that mitral valve repair is a reproducible and durable procedure. There are certain limitations of the study presented that warrant discussion. There are expected and inherent limitations of a retrospective study. In this particular series, we had a limited number of postoperative echocardiograms (31%) available for comparison with preoperative studies. Although this is a limitation of our study inherent to the retrospective design, we do have complete follow-up information regarding functional status and clinical outcome of all of our patients. No information in our particular population can be obtained regarding the number of patients who are asymptomatic or minimally asymptomatic and were not referred for surgical intervention. The NYHA functional classification system has limitations unto itself that may have altered the inclusion and exclusion process. Ideally, patients should be classified with provocative exercise testing, as many patients may self-limit their own activity level and therefore falsely report their actual functional status. Clear demonstration of the superiority of mitral reconstruction in patients with no symptoms or mild symptoms would require a randomized prospective study comparing optimal medical management with early surgical intervention. This study would be impossible to conduct in today s times, and may even be considered by some to be unethical, as virtually no patients would be available for the control group because many are referred earlier and earlier for surgical intervention. To advocate early surgical intervention for MR, two conditions should always be met: the valve must consistently be able to be repaired as opposed to being replaced, and operative mortality must approach zero [14]. In this series 100% of our patients underwent initial valve repair, with only 1 patient requiring replacement after repair failure. Additionally, we demonstrated a 0% operative mortality and a very low rate of procedure-related morbidity. We believe that surgical treatment of severe MR should be advocated in patients with no symptoms or only mild symptoms, as valve repair can be performed with no mortality and very low morbidity. Although our results with mitral valve repair in patients with NYHA functional class I and II are only intermediate to date, our

6 Ann Thorac Surg SMOLENS ET AL 2001;72: PROPHYLACTIC MITRAL RECONSTRUCTION 1215 results as well as those of others support the position that early surgical intervention can be undertaken in this patient population, with low morbidity and mortality. References 1. Cosgrove DM, Chavez AM, Lytle BW, et al. Results of mitral valve reconstruction. Circulation 1986;74: David TE, Armstrong S, Sun Z, et al. Late results of mitral valve repair for mitral regurgitation due to degenerative disease. Ann Thorac Surg 1993;56: David TE, Uden DE, Strauss HD. The importance of the mitral apparatus in left ventricular function after correction of mitral regurgitation. Circulation 1983;68:II Enriquez-Sarano M, Schaff H, Orszulak T, et al. Valve repair improves the outcome of surgery for mitral regurgitation. Circulation 1995;91: Galloway AC, Colvin SB, Baumann FG, et al. Long-term results of mitral valve reconstruction with Carpentier techniques in 148 patients with mitral insufficiency. Circulation 1988;78(3 Pt 2):I Lee EM, Shapiro LM, Wells FC. Superiority of mitral valve repair in surgery for degenerative mitral regurgitation. Eur Heart J 1997;18: Carabello BA, Crawford FA. Medical progress: valvular heart disease. N Engl J Med 1997;337: Enriquez-Sarano M, Orszulak TA, Schaff H, et al. Mitral regurgitation: a new clinical perspective. Mayo Clin Proc 1997;72: Mudge GH. Asymptomatic mitral regurgitation: when to operate? J Card Surg 1994;92: Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral valve prolapse. N Engl J Med 1999;341: Quinones MA. Management of mitral regurgitation: optimal timing for surgery. Cardiol Clin 1998;16: Sousa UM, Dreyfus G, Rescigno G, et al. Surgical treatment of asymptomatic and mildly symptomatic mitral regurgitation. J Thorac Cardiovasc Surg 1996;112: Starling MR. Effects of valve surgery on left ventricular contractile function in patients with long-term mitral regurgitation. Circulation 1995;92: Starling MR, Kirsh MM, Montgomery DG, et al. Impaired left ventricular contractile function in patients with longterm mitral regurgitation and normal ejection fraction. J Am Coll Cardiol 1993;22: Ling LH, Enriquez-Sarano M, Seward JB, et al. Clinical outcome of mitral regurgitation due to flail leaflet. N Engl J Med 1996;335: Ling LH, Enriquez-Sarano M, Seward JB, et al. Early surgery in patients with mitral regurgitation due to flail leaflets; a long-term outcome study. Circulation 1997;96: Gillinov AM, Cosgrove DM, Lytle BW, et al. Reoperation for failure of mitral valve repair. J Thorac Cardiovasc Surg 1997; 113: DISCUSSION DR DAVID H. ADAMS (Boston, MA): That was a very nice presentation. I think the ASD paradigm for mitral repair is something I believe we are also ready for. I wonder if members of the audience have questions. DR CARLOS DURAN (Missoula, MT): I congratulate you for this nice piece of work. I entirely agree with your statements that nowadays with good TEE it should be possible to determine before surgery the feasibility of valve repair. I am a little bit concerned, however, that people might use your numbers, go home, and tell the cardiologist, Send me every case you have of severe mitral regurgitation; I am going to repair them all. But unless they are quite familiar with TEE or TTE, and they can really reassure the patient that the chances of repair are well above 90%, it is going to be dangerous. I have one question. In the abstract, you mentioned that some of the patients had rheumatic disease, and now you are only talking about the myxomatous. Does that mean that you have changed your policy and that this applies only to myxomatous, or does it also apply to rheumatics with a good valve? That is, I am asking if you would recommend surgery to an asymptomatic patient with a rheumatic valve expected to be good for repair. DR SMOLENS: In this presentation, we included only those patients with degenerative mitral valve disease. Patients with rheumatic mitral valve disease are less amenable to mitral valve repair. Therefore, if an asymptomatic patient with rheumatic mitral valve disease were to present, it would be our general recommendation to follow this patient until symptoms were to develop. The data presented in this study should only be applied to those patients with degenerative mitral valve disease. DR IRVING L. KRON (Charlottesville, VA): I want to congratulate you on a great presentation. This is a classic Bolling presentation. You have done very well. The question I have is, are these patients truly asymptomatic? As you know, mitral valve disease is an insidious disease and we don t get to find these folks on the street. They tend to come to our office for some reason, and they usually have been seen by 2 or 3 other physicians. So typically a patient says, yes, they feel fine when they are sitting there. However, if you walk them down the hall they are short of breath, and in fact they are probably quite symptomatic. Can you tell me, what are your thoughts about that? If they have an exercise test and get short of breath, are they symptomatic? DR SMOLENS: I agree with you and I too suspect many patients may not be truly asymptomatic. NYHA classification is based on what the patient reports to the physician, and I think many patients limit their own activity to compensate for some of their own inabilities. Provocative exercise testing would be a helpful tool in better assessing the patients level of symptoms. At the University of Michigan, our cardiology colleagues have witnessed our success rate with mitral valve repair in these young, asymptomatic patients and in response have been referring the patients for surgical evaluation earlier and earlier in the disease process. Therefore many of the patients that we are now seeing are reliably in NYHA class I. DR BALJIT KUMAR SHARMA (Yakima, WA): I enjoyed your paper. A couple of questions. I would like to push this concept a little bit further. Suppose a patient comes to you who is asymptomatic but has atrial fibrillation. Would you still do the same thing? And if you would, why would you not try to do anything to atrial fibrillation, because these are the patients who might get more benefit by surgically treating their atrial fibrillation. Do you normally put them on Coumadin if they have atrial fibrillation, and for how long?

7 1216 SMOLENS ET AL Ann Thorac Surg PROPHYLACTIC MITRAL RECONSTRUCTION 2001;72: DR SMOLENS: Although the NYHA classification system for heart failure does not include atrial fibrillation as a symptom of failure, I do believe that these patients in atrial fibrillation are symptomatic. The atrial fibrillation is attributed to a chronic alteration in the atria, and I do think these patients should undergo mitral valve repair. Many patients will present with a history of paroxysmal atrial fibrillation that has responded to medical therapy and will be in normal sinus rhythm at the time of operation. In these patients, we advocate repair of the mitral valve alone. There is a second group of patients who present with atrial fibrillation and markedly enlarged atria. These patients would be considered for mitral valve repair in combination with an atrial reduction and Maze procedures. This subset of patients was not included this presentation. DR ADAMS: Just to follow-up and close with a couple of quick questions. What is the age cutoff? If you are 80 years old and you have asymptomatic regurgitation, should you undergo elective repair? The second question relates back to atrial fibrillation. Since these really are asymptomatic patients, I am hoping none of them are in atrial fibrillation. Were you able to avoid atrial fibrillation in the entire cohort? DR SMOLENS: We have no strict age cutoff. If the patient is elderly, with no other significant comorbidities, and is in a good state of health, mitral valve repair would be recommended. Eleven patients (11.3%) had a history of atrial arrhythmias at the time of their presentation for surgical evaluation. None of the patients had been in chronic atrial fibrillation. Eighteen patients (19.5%) developed atrial fibrillation in the immediate postoperative period (30 days), all of whom responded to either electrical or chemical cardioversion. All but 1 patient currently (1.1%) remain in normal sinus rhythm at follow-up. DR ADAMS: One final question, and that is, these are young patients having prophylactic valve surgery, so the bar is pretty high, and these are complicated repairs. You do a complicated repair and a postoperative TE echo shows one plus regurgitation, when do you go back and take a second look at the valve? DR SMOLENS: The postoperative TEE should be perfect. In our series only 1 patient required reinstitution of cardiopulmonary bypass to reinspect the valve. It was amenable to repair. In this situation, when a patient is presented for a prophylactic repair, they must leave the OR with a perfect repair. Southern Thoracic Surgical Association: Forty-eighth Annual Meeting The Forty-eighth Annual Meeting of the Southern Thoracic Surgical Association will be held November 8 10, 2001, San Antonio, Texas. The Postgraduate Course will be held the morning of Thursday, November 8, 2001, and will provide in-depth coverage of thoracic surgical topics selected primarily as a means to enhance and broaden the knowledge of practicing thoracic and cardiac surgeons. Carolyn E. Reed, MD Secretary/Treasurer Southern Thoracic Surgical Association 401 North Michigan Ave Chicago, IL (800) 685-STSA or (312) fax: (312) stsa@sba.com; by The Society of Thoracic Surgeons Ann Thorac Surg 2001;72: /01/$20.00 Published by Elsevier Science Inc

Outcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease

Outcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease Outcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease TIRONE E. DAVID, MD ; SEMIN THORAC CARDIOVASC SURG 19:116-120c 2007 ELSEVIER INC. PRESENTED BY INTERN 許士盟 Mitral valve

More information

Journal of the American College of Cardiology Vol. 42, No. 3, by the American College of Cardiology Foundation ISSN /03/$30.

Journal of the American College of Cardiology Vol. 42, No. 3, by the American College of Cardiology Foundation ISSN /03/$30. Journal of the American College of Cardiology Vol. 42, No. 3, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00649-1

More information

The risk-benefit ratio of mitral valve operation is

The risk-benefit ratio of mitral valve operation is Degenerative Mitral Regurgitation: When Should We Operate? Malcolm J. R. Dalrymple-Hay, PhD, Mark Bryant, Richard A. Jones, MRCP, Stephen M. Langley, FRCS, Steven A. Livesey, FRCS, and James L. Monro,

More information

Surgery for Valvular Heart Disease. Very Long-Term Survival and Durability of Mitral Valve Repair for Mitral Valve Prolapse

Surgery for Valvular Heart Disease. Very Long-Term Survival and Durability of Mitral Valve Repair for Mitral Valve Prolapse Surgery for Valvular Heart Disease Very Long-Term Survival and Durability of Mitral Valve Repair for Mitral Valve Prolapse Dania Mohty, MD; Thomas A. Orszulak, MD; Hartzell V. Schaff, MD; Jean-Francois

More information

The New England Journal of Medicine. Clinical Practice. Diagnosis. Echocardiography

The New England Journal of Medicine. Clinical Practice. Diagnosis. Echocardiography Clinical Practice This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines,

More information

Χειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας

Χειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας Χειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας Dr Χρήστος ΑΛΕΞΙΟΥ MD, PhD, FRCS(Glasgow), FRCS(CTh), CCST(UK) Consultant Cardiothoracic Surgeon Normal Mitral Valve Function Mitral Regurgitation

More information

What is the Role of Surgical Repair in 2012

What is the Role of Surgical Repair in 2012 What is the Role of Surgical Repair in 2012 The Long-Term Results of Surgery Raphael Rosenhek Department of Cardiology Medical University of Vienna European Society of Cardiology 2012 Munich, August 27th

More information

Ann Thorac Cardiovasc Surg 2015; 21: Online April 18, 2014 doi: /atcs.oa Original Article

Ann Thorac Cardiovasc Surg 2015; 21: Online April 18, 2014 doi: /atcs.oa Original Article Ann Thorac Cardiovasc Surg 2015; 21: 53 58 Online April 18, 2014 doi: 10.5761/atcs.oa.13-00364 Original Article The Impact of Preoperative and Postoperative Pulmonary Hypertension on Long-Term Surgical

More information

Mitral Valve Disease, When to Intervene

Mitral Valve Disease, When to Intervene Mitral Valve Disease, When to Intervene Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Current ACC/AHA guideline Stages

More information

Bicuspid aortic root spared during ascending aorta surgery: an update of long-term results

Bicuspid aortic root spared during ascending aorta surgery: an update of long-term results Short Communication Bicuspid aortic root spared during ascending aorta surgery: an update of long-term results Marco Russo, Guglielmo Saitto, Paolo Nardi, Fabio Bertoldo, Carlo Bassano, Antonio Scafuri,

More information

Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine

Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine Mitral regurgitation, regurgitant flow between the

More information

Recurrent mitral regurgitation after repair: Should the mitral valve be re-repaired?

Recurrent mitral regurgitation after repair: Should the mitral valve be re-repaired? Surgery for Acquired Cardiovascular Disease Recurrent mitral regurgitation after repair: Should the mitral valve be re-repaired? Rakesh M. Suri, MD, DPhil, Hartzell V. Schaff, MD, Joseph A. Dearani, MD,

More information

Long-Term Assessment of Mitral Valve Reconstruction With Resection of the Leaflets: Triangular and Quadrangular Resection

Long-Term Assessment of Mitral Valve Reconstruction With Resection of the Leaflets: Triangular and Quadrangular Resection Long-Term Assessment of Mitral Valve Reconstruction With Resection of the Leaflets: Triangular and Quadrangular Resection Yoshimasa Sakamoto, MD, Kazuhiro Hashimoto, MD, Hiroshi Okuyama, MD, Shinichi Ishii,

More information

Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?

Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles

More information

Isolated Mitral Valve Repair in Patients With Depressed Left Ventricular Function

Isolated Mitral Valve Repair in Patients With Depressed Left Ventricular Function Isolated Mitral Valve Repair in Patients With Depressed Left Ventricular Function Ashish S. Shah, MD, Steven A. Hannish, MD, Carmelo A. Milano, MD, and Donald D. Glower, MD Department of General and Thoracic

More information

Quality Outcomes Mitral Valve Repair

Quality Outcomes Mitral Valve Repair Quality Outcomes Mitral Valve Repair Moving Beyond Reoperation Rakesh M. Suri, D.Phil. Professor of Surgery 2015 MFMER 3431548-1 Disclosure Mayo Clinic Division of Cardiovascular Surgery Research funding

More information

Asymptomatic Valvular Disease:

Asymptomatic Valvular Disease: Asymptomatic Valvular Disease: Can Echocardiography Help You Decide When to Intervene? Neil J. Weissman, MD MedStar Health Research Inst at MedStar Washington Hospital Center & Professor of Medicine Georgetown

More information

The use of mitral valve (MV) repair to correct mitral

The use of mitral valve (MV) repair to correct mitral Outcomes and Long-Term Survival for Patients Undergoing Repair Versus Effect of Age and Concomitant Coronary Artery Bypass Grafting Vinod H. Thourani, MD; William S. Weintraub, MD; Robert A. Guyton, MD;

More information

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat Innovative Procedures, Devices & State of the Art Care for Arrhythmias, Heart Failure & Structural Heart Disease October 8-10,

More information

A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision

A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction

More information

16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900

16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 CLINICAL COMMUNIQUé 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 69 The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 69, was introduced into clinical

More information

8/31/2016. Mitraclip in Matthew Johnson, MD

8/31/2016. Mitraclip in Matthew Johnson, MD Mitraclip in 2016 Matthew Johnson, MD 1 Abnormal Valve Function Valve Stenosis Obstruction to valve flow during that phase of the cardiac cycle when the valve is normally open. Hemodynamic hallmark - pressure

More information

Percutaneous Mitral Valve Repair

Percutaneous Mitral Valve Repair Indiana Chapter of ACC November 15 th,2008 Percutaneous Mitral Valve Repair James B Hermiller, MD, FACC The Care Group, LLC St Vincent Hospital Indianapolis, IN Mechanisms of Mitral Regurgitation Mitral

More information

Degenerative mitral valve disease is the leading cause of

Degenerative mitral valve disease is the leading cause of Recurrence of Mitral Valve Regurgitation After Mitral Valve Repair in Degenerative Valve Disease Willem Flameng, MD, PhD; Paul Herijgers, MD, PhD; Kris Bogaerts, MSc Background Durability assessment of

More information

Influence of Atrial Fibrillation on Outcome Following Mitral Valve Repair

Influence of Atrial Fibrillation on Outcome Following Mitral Valve Repair Influence of Atrial Fibrillation on Outcome Following Mitral Valve Repair Eric Lim, MBChB, MRCS; Clifford W. Barlow, DPhil, FRCS; A. Reza Hosseinpour, FRCS; Christopher Wisbey, BA; Kate Wilson, RN, BSc;

More information

Clinical material and methods. Fukui Cardiovascular Center, Fukui, Japan

Clinical material and methods. Fukui Cardiovascular Center, Fukui, Japan Mitral Valve Regurgitation after Atrial Septal Defect Repair in Adults Shohei Yoshida, Satoshi Numata, Yasushi Tsutsumi, Osamu Monta, Sachiko Yamazaki, Hiroyuki Seo, Takaaki Samura, Hirokazu Ohashi Fukui

More information

Ischemic mitral valve reconstruction and replacement: Comparison of long-term survival and complications

Ischemic mitral valve reconstruction and replacement: Comparison of long-term survival and complications Surgery for Acquired Cardiovascular Disease Ischemic mitral valve reconstruction and replacement: Comparison of long-term survival and complications Eugene A. Grossi, MD Judith D. Goldberg, ScD Angelo

More information

Mitral Regurgitation

Mitral Regurgitation Mitral Regurgitation Focus on Percutaneous Repair Steven J. Yakubov, MD FACC FSCAI System Chief, Structural Heart Diseaese, OhioHealth John H. McConnell Chair of Advanced Structural Heart Disease Medical

More information

(Ann Thorac Surg 2008;85:845 53)

(Ann Thorac Surg 2008;85:845 53) I Made Adi Parmana The utility of intraoperative TEE has become increasingly more evident as anesthesiologists, cardiologists, and surgeons continue to appreciate its potential application as an invaluable

More information

Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention

Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention John N. Hamaty D.O. FACC, FACOI November 17 th 2017 I have no financial disclosures Primary Mitral

More information

Long term outcomes of posterior leaflet folding valvuloplasty for mitral valve regurgitation

Long term outcomes of posterior leaflet folding valvuloplasty for mitral valve regurgitation Featured Article Long term outcomes of posterior leaflet folding valvuloplasty for mitral valve regurgitation Igor Gosev 1, Maroun Yammine 1, Marzia Leacche 1, Siobhan McGurk 1, Vladimir Ivkovic 1, Michael

More information

Les valvulopathies en sourdine: la valve mitrale Quoi faire devant une régurgitation mitrale sévère asymptomatique de type dégénérative?

Les valvulopathies en sourdine: la valve mitrale Quoi faire devant une régurgitation mitrale sévère asymptomatique de type dégénérative? Réunion d automne de la SSC à Lucerne le 24.11.2011 Incertitudes dans le travail cardiologique quotidien Les valvulopathies en sourdine: la valve mitrale Quoi faire devant une régurgitation mitrale sévère

More information

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM The Patient with Aortic Stenosis and Mitral Regurgitation Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM Aortic Stenosis + Mitral Regurgitation?

More information

Repair or Replacement

Repair or Replacement Surgical intervention post MitraClip Device: Repair or Replacement Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division

More information

Which Type of Secondary Tricuspid Regurgitation Accompanying Mitral Valve Disease Should Be Surgically Treated?

Which Type of Secondary Tricuspid Regurgitation Accompanying Mitral Valve Disease Should Be Surgically Treated? Ann Thorac Cardiovasc Surg 2013; 19: 428 434 Online January 31, 2013 doi: 10.5761/atcs.oa.12.01929 Original Article Which Type of Secondary Tricuspid Regurgitation Accompanying Mitral Valve Disease Should

More information

TSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD

TSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD TSDA Boot Camp September 13-16, 2018 Introduction to Aortic Valve Surgery George L. Hicks, Jr., MD Aortic Valve Pathology and Treatment Valvular Aortic Stenosis in Adults Average Course (Post mortem data)

More information

Disclosure Statement of Financial Interest Saibal Kar, MD, FACC

Disclosure Statement of Financial Interest Saibal Kar, MD, FACC MitraClip Therapy Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Program Director, Interventional Cardiology Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA

More information

Late secondary TR after left sided heart disease correction: is it predictibale and preventable

Late secondary TR after left sided heart disease correction: is it predictibale and preventable Late secondary TR after left sided heart disease correction: is it predictibale and preventable Gilles D. Dreyfus Professor of Cardiothoracic surgery Nath J, et al. JACC 2004 PREDICT Incidence of secondary

More information

The Edge-to-Edge Technique f For Barlow's Disease

The Edge-to-Edge Technique f For Barlow's Disease The Edge-to-Edge Technique f For Barlow's Disease Ottavio Alfieri, Michele De Bonis, Elisabetta Lapenna, Francesco Maisano, Lucia Torracca, Giovanni La Canna. Department of Cardiac Surgery, San Raffaele

More information

Mitral valve surgery has changed considerably in the past decades and is now indicated

Mitral valve surgery has changed considerably in the past decades and is now indicated Valve disease TIMING OF MITRAL VALVE SURGERY c POOR Correspondence to: Dr Maurice Enriquez-Sarano, Mayo Clinic, 2 First Street SW, Rochester, MN 5595, USA; sarano.maurice@mayo.edu Copyright 22 Mayo Foundation

More information

Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan

Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan Degenerative MR is not Functional MR 2o - Functional MR : Ventricular Problem!!

More information

CLINICAL COMMUNIQUE 16 YEAR RESULTS

CLINICAL COMMUNIQUE 16 YEAR RESULTS CLINICAL COMMUNIQUE 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 Introduction The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 6900, was introduced

More information

Ischemic Mitral Valve Disease: Repair, Replace or Ignore?

Ischemic Mitral Valve Disease: Repair, Replace or Ignore? Ischemic Mitral Valve Disease: Repair, Replace or Ignore? Fabio B. Jatene Full Professor of Cardiovascular Surgery, Medical School, University of São Paulo, Brazil DISCLOSURE I have no financial relationship

More information

Catheter-based mitral valve repair MitraClip System

Catheter-based mitral valve repair MitraClip System Percutaneous Mitral Valve Repair: Results of the EVEREST II Trial William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular

More information

Long-term results (22 years) of the Ross Operation a single institutional experience

Long-term results (22 years) of the Ross Operation a single institutional experience Long-term results (22 years) of the Ross Operation a single institutional experience Authors: Costa FDA, Schnorr GM, Veloso M,Calixto A, Colatusso D, Balbi EM, Torres R, Ferreira ADA, Colatusso C Department

More information

PROSTHETIC VALVE BOARD REVIEW

PROSTHETIC VALVE BOARD REVIEW PROSTHETIC VALVE BOARD REVIEW The correct answer D This two chamber view shows a porcine mitral prosthesis with the typical appearance of the struts although the leaflets are not well seen. The valve

More information

The clinical problem of atrioventricular valve regurgitation

The clinical problem of atrioventricular valve regurgitation Mitral Regurgitation in Congenital Heart Defects: Surgical Techniques for Reconstruction Richard G. Ohye Mitral valve regurgitation (MR) is an important source of morbidity and mortality worldwide. While

More information

Percutaneous Mitral Valve Repair

Percutaneous Mitral Valve Repair Percutaneous Mitral Valve Repair MitraClip: Procedure, Data, Patient Selection Chad Rammohan, MD FACC Director, Cardiac Cath Lab El Camino Hospital Mountain View, California Mitral Regurgitation MitraClip

More information

Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?

Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? RM Suri, V Sharma, JA Dearani, HM Burkhart, RC Daly, LD Joyce, HV Schaff Division of Cardiovascular Surgery, Mayo Clinic, Rochester,

More information

Understanding the guidelines for Interventions in MR. Ali AlMasood

Understanding the guidelines for Interventions in MR. Ali AlMasood Understanding the guidelines for Interventions in MR Ali AlMasood Mitral regurgitation The most diverse from all acquired valve diseases About 50% of patients with an LVEF 35 percent had moderate to severe

More information

Really Less-Invasive Trans-apical Beating Heart Mitral Valve Repair: Which Patients?

Really Less-Invasive Trans-apical Beating Heart Mitral Valve Repair: Which Patients? Really Less-Invasive Trans-apical Beating Heart Mitral Valve Repair: Which Patients? David H. Adams, MD Cardiac Surgeon-in-Chief Mount Sinai Health System Marie Josée and Henry R. Kravis Professor and

More information

Adult Echocardiography Examination Content Outline

Adult Echocardiography Examination Content Outline Adult Echocardiography Examination Content Outline (Outline Summary) # Domain Subdomain Percentage 1 2 3 4 5 Anatomy and Physiology Pathology Clinical Care and Safety Measurement Techniques, Maneuvers,

More information

Degenerative mitral valve disease is now the most common

Degenerative mitral valve disease is now the most common Triangular Resection for Repair of Mitral Regurgitation Due to Degenerative Disease Rakesh M. Suri, MD, DPhil, FRCS(C), and Thomas A. Orszulak, MD, FACC Degenerative mitral valve disease is now the most

More information

Mitral valve repair is the gold standard to treat mitral regurgitation.

Mitral valve repair is the gold standard to treat mitral regurgitation. Papillary muscle repositioning for repair of anterior leaflet prolapse caused by chordal elongation Gilles D. Dreyfus, MD, PhD, FRCS, Olivio Souza Neto, MD, and Stéphane Aubert, MD, MSc Objective: Anterior

More information

When should we intervene surgically in pediatric patient with MR?

When should we intervene surgically in pediatric patient with MR? When should we intervene surgically in pediatric patient with MR? DR.SAUD A. BAHAIDARAH CONSULTANT, PEDIATRIC CARDIOLOGY ASSISTANT PROFESSOR OF PEDIATRICS HEAD OF CARDIOLOGY AND CARDIAC SURGERY UNIT KAUH

More information

Posterior leaflet prolapse is the most common lesion seen

Posterior leaflet prolapse is the most common lesion seen Techniques for Repairing Posterior Leaflet Prolapse of the Mitral Valve Robin Varghese, MD, MS, and David H. Adams, MD Posterior leaflet prolapse is the most common lesion seen in degenerative mitral valve

More information

Restoration of Sinus Rhythm by the Maze Procedure Halts Progression of Tricuspid Regurgitation After Mitral Surgery

Restoration of Sinus Rhythm by the Maze Procedure Halts Progression of Tricuspid Regurgitation After Mitral Surgery Restoration of Sinus Rhythm by the Maze Procedure Halts Progression of Tricuspid Regurgitation After Mitral Surgery John M. Stulak, MD,* Hartzell V. Schaff, MD, Joseph A. Dearani, MD, Thomas A. Orszulak,

More information

Case # 1. Page: 8. DUKE: Adams

Case # 1. Page: 8. DUKE: Adams Case # 1 Page: 8 1. The cardiac output in this patient is reduced because of: O a) tamponade physiology O b) restrictive physiology O c) coronary artery disease O d) left bundle branch block Page: 8 1.

More information

Valve Analysis and Pathoanatomy: THE MITRAL VALVE

Valve Analysis and Pathoanatomy: THE MITRAL VALVE : THE MITRAL VALVE Marc R. Moon, M.D. John M. Shoenberg Chair in CV Disease Chief, Cardiac Surgery Washington University School of Medicine, St. Louis, MO Secretary, American Association for Thoracic Surgery

More information

Failure of Guideline Adherence for Intervention in Patients With Severe Mitral Regurgitation

Failure of Guideline Adherence for Intervention in Patients With Severe Mitral Regurgitation Journal of the American College of Cardiology Vol. 54, No. 9, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.03.079

More information

Nikos Kouris a, *, Ignatios Ikonomidis b, Dimitra Kontogianni a, Peter Smith b, Petros Nihoyannopoulos b

Nikos Kouris a, *, Ignatios Ikonomidis b, Dimitra Kontogianni a, Peter Smith b, Petros Nihoyannopoulos b Eur J Echocardiography (2005) 6, 435e442 Mitral valve repair versus replacement for isolated non-ischemic mitral regurgitation in patients with preoperative left ventricular dysfunction. A long-term follow-up

More information

Mitral Valve Repair for 52 Patients with Severe Left Ventricular Dysfunction

Mitral Valve Repair for 52 Patients with Severe Left Ventricular Dysfunction Original Article Mitral Valve Repair for 52 Patients with Severe Left Ventricular Dysfunction Mikiko Murakami, MD, Hiroki Yamaguchi, MD, PhD, Yuji Suda, MD, PhD, Tomohiro Asai, MD, PhD, Michiaki Sueishi,

More information

Diversion of the inferior vena cava following repair of atrial septal defect causing hypoxemia

Diversion of the inferior vena cava following repair of atrial septal defect causing hypoxemia Marshall University Marshall Digital Scholar Internal Medicine Faculty Research Spring 5-2004 Diversion of the inferior vena cava following repair of atrial septal defect causing hypoxemia Ellen A. Thompson

More information

Valve Repair for Mitral Regurgitation Caused by Isolated Prolapse of the Posterior Leaflet

Valve Repair for Mitral Regurgitation Caused by Isolated Prolapse of the Posterior Leaflet Valve Repair for Mitral Regurgitation Caused by Isolated Prolapse of the Posterior Leaflet Patrick Perier, MD, J/2rgen Stumpf, MD, Christian GStz, MD, Fitsoum Lakew, MD, Andr6 Schneider, MD, Bernd Clausnizer,

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter

More information

Despite advances in our understanding of the pathophysiology

Despite advances in our understanding of the pathophysiology Suture Relocation of the Posterior Papillary Muscle in Ischemic Mitral Regurgitation Benjamin B. Peeler MD,* and Irving L. Kron MD,*, *Department of Cardiovascular Surgery, University of Virginia, Charlottesville,

More information

Chronic Primary Mitral Regurgitation

Chronic Primary Mitral Regurgitation Chronic Primary Mitral Regurgitation The Case For Early Surgical Intervention William K. Freeman, MD, FACC, FASE DISCLOSURES Relevant Financial Relationship(s) None Off Label Usage None Watchful Waiting......

More information

Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz

Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia Decision process for

More information

Assessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington

Assessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME

More information

Reconstruction of the intervalvular fibrous body during aortic and

Reconstruction of the intervalvular fibrous body during aortic and Aortic and mitral valve replacement with reconstruction of the intervalvular fibrous body: An analysis of clinical outcomes Nilto C. De Oliveira, MD Tirone E. David, MD Susan Armstrong, MSc Joan Ivanov,

More information

Professor and Chief, Division of Cardiac Surgery Chief Medical Officer, Harpoon Medical. The Houston Aortic Symposium February 23-25, 2017

Professor and Chief, Division of Cardiac Surgery Chief Medical Officer, Harpoon Medical. The Houston Aortic Symposium February 23-25, 2017 James S. Gammie, MD Professor and Chief, Division of Cardiac Surgery Chief Medical Officer, Harpoon Medical The Houston Aortic Symposium February 2-25, 2017 Disclosure Statement of Financial Interest Within

More information

Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017

Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017 Disclosures: GE stock, Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017 Athena Poppas, MD FACC Past ACC Scientific Sessions Chair, ACC Board

More information

Historical perspective R1 黃維立

Historical perspective R1 黃維立 Degenerative mitral valve disease refers to a spectrum of conditions in which morphologic changes in the connective tissue of the mitral valve cause structural lesions that prevent normal function of the

More information

Organic mitral regurgitation

Organic mitral regurgitation The best in heart valve disease Organic mitral regurgitation Ewa Szymczyk Department of Cardiology Medical University of Lodz, Poland I have nothing to declare Organic mitral regurgitation leaflet abnormality

More information

Durability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement

Durability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement Durability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement Masaki Hamamoto, MD, Ko Bando, MD, Junjiro Kobayashi, MD, Toshihiko Satoh, MD, MPH, Yoshikado

More information

Although most surgeons would agree that severe mitral

Although most surgeons would agree that severe mitral Does Coronary Artery Bypass Grafting Alone Correct Moderate Ischemic Mitral Regurgitation? Lishan Aklog, MD; Farzan Filsoufi, MD; Kathryn Q. Flores, MD; Raymond H. Chen, MD; Lawrence H. Cohn, MD; Nadia

More information

Cases of mitral valve causing mitral regurgitation: the MV prolapse spectrum CASE

Cases of mitral valve causing mitral regurgitation: the MV prolapse spectrum CASE Cases of mitral valve causing mitral regurgitation: the MV prolapse spectrum Judy Hung, MD Cardiology Division Massachusetts General Hospital Boston, MA CASE Mr. M; 50 Year male presents to internist for

More information

Midterm Outcomes Using the Physio Ring in Mitral Valve Reconstruction: Experience in 492 Patients

Midterm Outcomes Using the Physio Ring in Mitral Valve Reconstruction: Experience in 492 Patients Midterm Outcomes Using the Physio Ring in Mitral Valve Reconstruction: Experience in 492 Patients Kevin D. Accola, MD, Meredith L. Scott, MD, Paul A. Thompson, MD, George J. Palmer III, MD, Mark E. Sand,

More information

Bogdan A. Popescu. University of Medicine and Pharmacy Bucharest, Romania. EAE Course, Bucharest, April 2010

Bogdan A. Popescu. University of Medicine and Pharmacy Bucharest, Romania. EAE Course, Bucharest, April 2010 Bogdan A. Popescu University of Medicine and Pharmacy Bucharest, Romania EAE Course, Bucharest, April 2010 This is how it started Mitral stenosis at a glance 2D echo narrow diastolic opening of MV leaflets

More information

Myxomatous degeneration of the mitral valve is the

Myxomatous degeneration of the mitral valve is the CARDIOVASCULAR Midterm Results of the Edge-to-Edge Technique for Complex Mitral Valve Repair Derek R. Brinster, MD, Daniel Unic, MD, Michael N. D Ambra, MD, Nadia Nathan, MD, and Lawrence H. Cohn, MD Division

More information

The production of murmurs is due to 3 main factors:

The production of murmurs is due to 3 main factors: Heart murmurs The production of murmurs is due to 3 main factors: high blood flow rate through normal or abnormal orifices forward flow through a narrowed or irregular orifice into a dilated vessel or

More information

Surgical Repair of the Mitral Valve Presenter: Graham McCrystal Cardiothoracic Surgeon Christchurch Public Hospital

Surgical Repair of the Mitral Valve Presenter: Graham McCrystal Cardiothoracic Surgeon Christchurch Public Hospital Mitral Valve Surgical intervention Graham McCrystal Chairs: Rajesh Nair & Gerard Wilkins Surgical Repair of the Mitral Valve Presenter: Graham McCrystal Cardiothoracic Surgeon Christchurch Public Hospital

More information

Surgical Mininvasive Approach for Mitral Repair Prof. Mauro Rinaldi

Surgical Mininvasive Approach for Mitral Repair Prof. Mauro Rinaldi Surgical Mininvasive Approach for Mitral Repair Prof. Mauro Rinaldi SC Cardiochirurgia U Universita degli Studi di Torino PORT-ACCESS TECNIQUE Reduce surgical trauma Minimize disruption of the chest wall

More information

Management of HOCM: Non-Surgical Options

Management of HOCM: Non-Surgical Options Management of HOCM: Non-Surgical Options Howard C. Herrmann, MD, FACC, MSCAI John Bryfogle Professor of Cardiovascular Medicine and Surgery Health System Director for Interventional Cardiology Director,

More information

Mitral Valve Repair at King Chulalongkorn Memorial Hospital; A Preliminary Report.

Mitral Valve Repair at King Chulalongkorn Memorial Hospital; A Preliminary Report. Mitral Valve Repair at King Chulalongkorn Memorial Hospital; A Preliminary Report. Jiranut Cholteesupachai, MD.*, Smonporn Boonyaratavej Songmuang, MD.*, Seri Singhatanadgige, MD. ** King Chulalongkorn

More information

Surgical repair techniques for IMR: future percutaneous options?

Surgical repair techniques for IMR: future percutaneous options? Surgical repair techniques for IMR: can this teach us about future percutaneous options? Genk - Belgium Prof. Dr. R. Dion KULeu Disclosure slide Robert A. Dion I disclose the following financial relationships:

More information

Common Codes for ICD-10

Common Codes for ICD-10 Common Codes for ICD-10 Specialty: Cardiology *Always utilize more specific codes first. ABNORMALITIES OF HEART RHYTHM ICD-9-CM Codes: 427.81, 427.89, 785.0, 785.1, 785.3 R00.0 Tachycardia, unspecified

More information

PATIENT BOOKLET MEDTRONIC MITRAL AND TRICUSPID HEART VALVE REPAIR

PATIENT BOOKLET MEDTRONIC MITRAL AND TRICUSPID HEART VALVE REPAIR PATIENT BOOKLET MEDTRONIC MITRAL AND TRICUSPID HEART VALVE REPAIR ARE MEDTRONIC HEART VALVE REPAIR THERAPIES RIGHT FOR YOU? Prosthetic (artificial) heart valve repair products are used by physicians to

More information

ORIGINAL PAPER. The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan

ORIGINAL PAPER. The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan Nagoya J. Med. Sci. 78. 369 ~ 376, 2016 doi:10.18999/nagjms.78.4.369 ORIGINAL PAPER The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan

More information

Heart Valves: Before and after surgery

Heart Valves: Before and after surgery Heart Valves: Before and after surgery Tim Sutton, Consultant Cardiologist Middlemore Hospital, Auckland Auckland Heart Group Indications for intervention in Valvular disease To prevent sudden death and

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Acute coronary syndrome(s), anticoagulant therapy in, 706, 707 antiplatelet therapy in, 702 ß-blockers in, 703 cardiac biomarkers in,

More information

Outcome of mitral valve repair in patients with preoperative atrial fibrillation

Outcome of mitral valve repair in patients with preoperative atrial fibrillation Outcome of mitral valve repair in patients with preoperative atrial fibrillation Should the maze procedure be combined with mitral valvuloplasty? To examine late outcome of mitral valve repair in patients

More information

Management of Difficult Aortic Root, Old and New solutions

Management of Difficult Aortic Root, Old and New solutions Management of Difficult Aortic Root, Old and New solutions Hani K. Najm MD, Msc, FRCSC,, FACC, FESC Chairman, Pediatric and Congenital Heart Surgery Cleveland Clinic Conflict of Interest None Difficult

More information

Atrioventricular valve repair: The limits of operability

Atrioventricular valve repair: The limits of operability Atrioventricular valve repair: The limits of operability Francis Fynn-Thompson, MD Co-Director, Center for Airway Disorders Surgical Director, Pediatric Mechanical Support Program Surgical Director, Heart

More information

Left ventricle pseudoaneurysm as late postoperative complication of a large apical aneurysm

Left ventricle pseudoaneurysm as late postoperative complication of a large apical aneurysm CASE REPORT Left ventricle pseudoaneurysm as late postoperative complication of a large apical aneurysm Mariana M. Floria 1, 4, Carmen Elena Pleșoianu 2, 4, Michel Buche 3, Baudouin Marchandise 4, Erwin

More information

Reoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment

Reoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment Reoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment W.R.E. Jamieson, MD; L.H. Burr, MD; R.T. Miyagishima, MD; M.T. Janusz, MD; G.J. Fradet, MD; S.V. Lichtenstein, MD; H. Ling, MD Background

More information

Presenter Disclosure. Patrick O. Myers, M.D. No Relationships to Disclose

Presenter Disclosure. Patrick O. Myers, M.D. No Relationships to Disclose Presenter Disclosure Patrick O. Myers, M.D. No Relationships to Disclose Aortic Valve Repair by Cusp Extension for Rheumatic Aortic Insufficiency in Children Long term Results and Impact of Extension Material

More information

We present the case of an asymptomatic, 75-year-old

We present the case of an asymptomatic, 75-year-old Images in Cardiovascular Medicine Asymptomatic Rupture of the Left Ventricle Lech Paluszkiewicz, MD; Stefan Ożegowski, MD; Mohammad Amin Parsa, MD; Jan Gummert, PhD, MD We present the case of an asymptomatic,

More information

Contemporary outcomes for surgical mitral valve repair: A benchmark for evaluating emerging mitral valve technology

Contemporary outcomes for surgical mitral valve repair: A benchmark for evaluating emerging mitral valve technology Contemporary outcomes for surgical mitral valve repair: A benchmark for evaluating emerging mitral valve technology Damien J. LaPar, MD, MSc, Daniel P. Mulloy, MD, Ivan K. Crosby, MBBS, D. Scott Lim, MD,

More information

Management of Tricuspid Regurgitation

Management of Tricuspid Regurgitation Management of Tricuspid Regurgitation Antonis A. Pitsis, FETCS, FESC Thessaloniki Heart Institute, St. Luke s Hospital, Thessaloniki, GREECE HEART FAILURE 2012 BELGRADE SERBIA Does Tricuspid Regurgitation

More information